Ligand Pharmaceuticals (LGND) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.98% |
| Dec 31, 2025 | 7.47% |
| Sep 30, 2025 | 6.37% |
| Jun 30, 2025 | 3.55% |
| Mar 31, 2025 | 3.75% |
| Dec 31, 2024 | 1.60% |
| Sep 30, 2024 | -0.22% |
| Jun 30, 2024 | -5.73% |
| Mar 31, 2024 | -5.67% |
| Dec 31, 2023 | 4.56% |
| Sep 30, 2023 | -0.92% |
| Jun 30, 2023 | 1.41% |
| Mar 31, 2023 | 6.08% |
| Dec 31, 2022 | 8.37% |
| Sep 30, 2022 | 15.15% |
| Jun 30, 2022 | 15.81% |
| Mar 31, 2022 | 16.36% |
| Dec 31, 2021 | 19.20% |
| Jun 30, 2021 | 14.95% |
| Mar 31, 2021 | 13.72% |
| Dec 31, 2020 | 24.49% |
| Sep 30, 2020 | 19.02% |
| Jun 30, 2020 | 58.69% |
| Mar 31, 2020 | 79.88% |
| Dec 31, 2019 | 99.29% |
| Sep 30, 2019 | 80.52% |
| Jun 30, 2019 | 74.61% |
| Mar 31, 2019 | 75.43% |
| Dec 31, 2018 | 62.43% |
| Sep 30, 2018 | 73.25% |
| Jun 30, 2018 | 73.64% |
| Mar 31, 2018 | 73.51% |
| Dec 31, 2017 | 72.09% |
| Sep 30, 2017 | 80.17% |
| Jun 30, 2017 | 85.62% |
| Dec 31, 2016 | 110.87% |
| Jun 30, 2016 | 131.70% |
| Dec 31, 2015 | 119.47% |